Prevention and therapy of neutropenia in elderly patients

Critical Reviews in Oncology/Hematology

Volumn 46, Issue 3, 2003, Pages 247-253

  Rosti, Giovanni ^a   Kopf, Barbara ^a   Cariello, Anna ^a   Monti, Manlio ^a   Dazzi, Claudio ^a   Papiani, Giorgio ^a   Giovanis, Petros ^a   De Giorgi, Ugo ^a   Marangolo, Maurizio ^a  

^a Ospedale Civile   (Italy)

Author keywords

Chemotherapy; Elderly patients; Haematopoietic growth factors; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; COLONY STIMULATING FACTOR; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOGLOBIN; HEMOPOIETIC GROWTH FACTOR; INTERLEUKIN 3; INTERLEUKIN 6; METHOTREXATE; PACLITAXEL; RITUXIMAB; TUMOR NECROSIS FACTOR; VINBLASTINE;

ADJUVANT CHEMOTHERAPY; AGING; ANEMIA; B CELL LYMPHOMA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BREAST CANCER; CONFERENCE PAPER; DISEASE SEVERITY; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; DRUG TOLERANCE; ELDERLY CARE; FATIGUE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HIGH RISK POPULATION; HUMAN; INFECTION; MICROENVIRONMENT; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRACTICE GUIDELINE; PRIMARY PREVENTION; STRESS; THROMBOCYTOPENIA;

EID: 0038520922     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(03)00024-6     Document Type: Conference Paper

References (30)

1. Yankee R., Rise L.A.G. Aging and cancer in America: demographic and epidemiological perspectives. Heamat. Oncol. Clin. North Am. 14:2000;17-23.
2. Polychemotherapy for early breast cancer: an overview of the randomised trails. Lancet. 352:1998;930-942.
3. National Institutes of Health. Adjuvant therapy for breast cancer. NIH consensus statement online 2000;17:1-23. http://odp.od.nih.gov/consensus/114/_intro.htm.
4. Du X., Goodwin J.S. Increase of chemotherapy use in older women with breast carcinoma from 1991 to 1996. Cancer. 92:2001;730-737.
5. Stuck A.E., Siu A.L., Wieland G.D., Adams J., Rubensetin L.Z. Comprehensive geriatric assessment: a meta-analysis of controlled trials. Lancet. 342:1993;1032-1036.
6. Ibrahim N.K., Frye D.K., Buzdar A.U., Walters R.S., Hortobagyi G.N. Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Arch. Inter. Med. 156:1996;882-888.
7. Christmas K., Muss H.B., Case L.D., Stanley V. Chemotherapy of metastatic breast cancer in the elderly. The Piedmont Oncology Association Experience. J. Am. Med. Assoc. 268:1992;57-62.
8. Lipschitz D.A. Age-related declines in hematopoietic reserve capacity. Semin. Oncol. 22:(suppl 1):1995;3-5.
9. Chatta G.S., Price T.H., Allen R.C., et al. Effects of in vivo recombinant granulocyte colony stimulating factor on the neutrophil response and peripheral blood colony-forming cells in healthy young and adult volunteers. Blood. 84:1994;2923-2929.
10. Balducci L., Hardy C.L., Lyman G.H. Hemopoietic reserve in the older cancer patient: clinical and economic considerations. Cancer Control. 7:2000;539-547.
11. + cells to hematopoietic growth factors and remodeling of cytokine network. J. Geront. A Biol. Sci. Med. 55:2000;61-66.
12. Globerson A. Hematopoietic stem cells and ageing. Globerson A. Exp. Gerontol. 34:1999;137-146.
13. Talcott J.A., Siegel R.D., Finberg R., Goldman L. Risk assessment in cancer patients with fever and neutropenia: prospective, two-center validation of a prediction rule. J. Clin. Oncol. 10:1992;316-322.
14. Balducci L., Extermann M. Management of cancer in the older person: a practical approach. Oncologist. 5:2000;224-237.
15. Crivellari D., Bonetti M., Castiglione-Gertsch M., et al. Burdens and benefits of adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil and Tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. J. Clin. Oncol. 18:2000;1412-1422.
16. Dees E.C., O'Reilly S., Goodman S.N., et al. A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in woman with breast cancer. Cancer Invest. 18:2000;521-529.
17. Ibrahim N.K., Buzdar A.U., Asmar L., et al. Doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients: The M.D. Anderson experience, with long term follow-up. Ann. Oncol. 11:2000;1597-1601.
18. Hainsworth J.D., Burris H.A. III, Yardley D.A., et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network Phase II study. J. Clin. Oncol. 19:2001;3500-3505.
19. Repetto L., Pietropaolo M., Granata R., et al. Weekly paclitaxel infusion in elderly patients with solid tumors. Tumori. S1:2002;S39-S40.
20. Hutchins L.F., Unger J.M., Crowley J.J., Coltman C.A. Jr, Albain K.S. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. New Engl. J. Med. 341:1999;2061-2067.
21. Dixon D.O., Neilan B., Jones S.E., et al. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. J. Clin. Oncol. 4:1996;295-305.
22. Zinzani P.L., Storti S., Zaccaria A., et al. Elderly aggressive-histology non-Hodgkin lymphoma: first-line VNCOP-B regimen. Experience on 350 patients. Blood. 94:1999;33-38.
23. Gòmez H., Hidalgo M., Casanova L., et al. Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: results of a multivariate analysis. J. Clin. Oncol. 16:1998;2065-2069.
24. Coiffier B., Lepage E., Brière J., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. New Engl. J. Med. 346:2002;235-242.
25. Björkholm M., Osby E., Hagberg H., et al. Randomised trial of r-metHu granulocyte-colony stimulating factor (G-CSF) as adjunct to CHOP or CNOP treatment of elderly patients with aggressive non-Hodgkin lymphoma. Blood. 94:1999;599. a. abstract 2665.
26. Zagonel V., Babare R., Merola M.C., et al. Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin lymphoma treated with combination chemotherapy. Ann. Oncol. 5:(suppl 2):1994;127-132.
27. de Graaf H., Willemse P.H.B., Bong S.B., et al. Dose intensity of standard adjuvant CMF with granulocyte colony-stimulating factor for premenopausal women with node-positive breast cancer. Oncology. 53:1996;289-294.
28. Bertini M., Freilone R., Vitolo U., et al. The treatment of elderly patients with aggressive non-Hodgkin lymphomas: feasibility and efficacy of an intensive multidrug regimen. Leuk. Lymph. 22:1996;483.
29. Ozer H., Armitage J.O., Bennet C.L., et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J. Clin. Oncol. 18:2000;3558-3585.
30. Balducci L., Yates J. General guidelines for the management of older patients with cancer. NCCN proceedings. Oncology. 14:2000;221-227.